Maxim Group analyst Anthony Vendetti has maintained their neutral stance on JYNT stock, giving a Hold rating yesterday.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Anthony Vendetti has given his Hold rating due to a combination of factors related to both recent performance and forward-looking risks. While the company delivered stronger-than-expected quarterly results and is showing early benefits from its new pain-relief marketing strategy, he believes these improvements are not yet sufficient to signal a sustained acceleration in growth.
He also points to ongoing macroeconomic pressures, uncertainty tied to the ongoing refranchising of company-owned clinics, and only gradual progress in expanding into underpenetrated regions as constraints on near-term upside. With modestly reduced revenue and earnings projections and limited visible catalysts until conditions improve and refranchising is largely completed, he concludes that the stock’s risk/reward profile is currently balanced, justifying a Hold stance rather than a more aggressive rating.
According to TipRanks, Vendetti is an analyst with an average return of -24.4% and a 24.85% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Icecure Medical, Daxor, and Nuwellis.
In another report released yesterday, B. Riley Securities also maintained a Hold rating on the stock with a $9.00 price target.